S&P 500   3,941.63 (-0.18%)
DOW   32,063.96 (-0.13%)
QQQ   308.19 (-0.50%)
AAPL   158.33 (-0.38%)
MSFT   277.59 (-0.03%)
META   204.08 (-0.10%)
GOOGL   104.54 (-1.00%)
AMZN   97.06 (-1.67%)
TSLA   188.17 (-2.11%)
NVDA   264.75 (-2.63%)
NIO   8.93 (-3.67%)
BABA   85.84 (-0.79%)
AMD   97.22 (-3.05%)
T   18.50 (+0.22%)
F   11.41 (-0.09%)
MU   60.65 (-1.12%)
CGC   1.90 (-0.28%)
GE   91.79 (+0.22%)
DIS   93.33 (-2.61%)
AMC   4.44 (-0.67%)
PFE   40.17 (-0.02%)
PYPL   72.98 (+0.58%)
NFLX   326.43 (+1.89%)
S&P 500   3,941.63 (-0.18%)
DOW   32,063.96 (-0.13%)
QQQ   308.19 (-0.50%)
AAPL   158.33 (-0.38%)
MSFT   277.59 (-0.03%)
META   204.08 (-0.10%)
GOOGL   104.54 (-1.00%)
AMZN   97.06 (-1.67%)
TSLA   188.17 (-2.11%)
NVDA   264.75 (-2.63%)
NIO   8.93 (-3.67%)
BABA   85.84 (-0.79%)
AMD   97.22 (-3.05%)
T   18.50 (+0.22%)
F   11.41 (-0.09%)
MU   60.65 (-1.12%)
CGC   1.90 (-0.28%)
GE   91.79 (+0.22%)
DIS   93.33 (-2.61%)
AMC   4.44 (-0.67%)
PFE   40.17 (-0.02%)
PYPL   72.98 (+0.58%)
NFLX   326.43 (+1.89%)
S&P 500   3,941.63 (-0.18%)
DOW   32,063.96 (-0.13%)
QQQ   308.19 (-0.50%)
AAPL   158.33 (-0.38%)
MSFT   277.59 (-0.03%)
META   204.08 (-0.10%)
GOOGL   104.54 (-1.00%)
AMZN   97.06 (-1.67%)
TSLA   188.17 (-2.11%)
NVDA   264.75 (-2.63%)
NIO   8.93 (-3.67%)
BABA   85.84 (-0.79%)
AMD   97.22 (-3.05%)
T   18.50 (+0.22%)
F   11.41 (-0.09%)
MU   60.65 (-1.12%)
CGC   1.90 (-0.28%)
GE   91.79 (+0.22%)
DIS   93.33 (-2.61%)
AMC   4.44 (-0.67%)
PFE   40.17 (-0.02%)
PYPL   72.98 (+0.58%)
NFLX   326.43 (+1.89%)
S&P 500   3,941.63 (-0.18%)
DOW   32,063.96 (-0.13%)
QQQ   308.19 (-0.50%)
AAPL   158.33 (-0.38%)
MSFT   277.59 (-0.03%)
META   204.08 (-0.10%)
GOOGL   104.54 (-1.00%)
AMZN   97.06 (-1.67%)
TSLA   188.17 (-2.11%)
NVDA   264.75 (-2.63%)
NIO   8.93 (-3.67%)
BABA   85.84 (-0.79%)
AMD   97.22 (-3.05%)
T   18.50 (+0.22%)
F   11.41 (-0.09%)
MU   60.65 (-1.12%)
CGC   1.90 (-0.28%)
GE   91.79 (+0.22%)
DIS   93.33 (-2.61%)
AMC   4.44 (-0.67%)
PFE   40.17 (-0.02%)
PYPL   72.98 (+0.58%)
NFLX   326.43 (+1.89%)
NASDAQ:ETNB

89bio - ETNB Stock Forecast, Price & News

$16.15
-0.79 (-4.66%)
(As of 03/24/2023 12:27 PM ET)
Add
Compare
Today's Range
$15.75
$18.03
50-Day Range
$10.50
$16.94
52-Week Range
$2.00
$18.03
Volume
5.85 million shs
Average Volume
1.97 million shs
Market Capitalization
$843.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.38

89bio MarketRank™ Forecast

Analyst Rating
Buy
3.13 Rating Score
Upside/​Downside
89.8% Upside
$33.25 Price Target
Short Interest
Bearish
9.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of 89bio in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$177,844 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.44) to ($2.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

619th out of 989 stocks

Pharmaceutical Preparations Industry

293rd out of 480 stocks


ETNB stock logo

About 89bio (NASDAQ:ETNB) Stock

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

ETNB Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
89bio (NASDAQ:ETNB) PT Raised to $33.00
89bio (NASDAQ:ETNB) PT Raised to $30.00 at HC Wainwright
Why Is 89bio (ETNB) Stock Up 34% Today?
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Orbimed Advisors Reduces Position in 89bio
89bio Provides Business Update and Outlook for 2023
See More Headlines
Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

ETNB Company Calendar

Last Earnings
11/11/2021
Today
3/24/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ETNB
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.25
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+49.8%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Net Income
$-102,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.00 per share

Miscellaneous

Free Float
46,068,000
Market Cap
$884.78 million
Optionable
Not Optionable
Beta
0.73

Key Executives

  • Mr. Rohan PalekarMr. Rohan Palekar (Age 56)
    CEO & Director
    Comp: $829.41k
  • Mr. Quoc Le-Nguyen (Age 54)
    Chief Technical Operations Officer & Head of Quality
    Comp: $571.12k
  • Dr. Harry Mansbach M.D. (Age 57)
    Chief Medical Officer
    Comp: $603.22k
  • Mr. Ryan Stephen Martins (Age 44)
    Chief Financial Officer
  • Mr. Shiva K. Natarajan (Age 56)
    Sr. VP of Fin. & Principal Accounting Officer
  • Ms. Melissa Abel
    Sr. VP of Commercial Strategy & Communications
  • Ms. Amanda Hill
    VP of People & Culture
  • Ms. Yun Bai
    VP & Head of CMC
  • Mr. Paul Shin
    Sr. VP of R&D Operations













ETNB Stock - Frequently Asked Questions

Should I buy or sell 89bio stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ETNB shares.
View ETNB analyst ratings
or view top-rated stocks.

What is 89bio's stock price forecast for 2023?

8 brokers have issued twelve-month target prices for 89bio's shares. Their ETNB share price forecasts range from $19.00 to $50.00. On average, they predict the company's stock price to reach $33.25 in the next twelve months. This suggests a possible upside of 96.3% from the stock's current price.
View analysts price targets for ETNB
or view top-rated stocks among Wall Street analysts.

How have ETNB shares performed in 2023?

89bio's stock was trading at $12.73 at the beginning of the year. Since then, ETNB stock has increased by 33.1% and is now trading at $16.94.
View the best growth stocks for 2023 here
.

Are investors shorting 89bio?

89bio saw a increase in short interest in February. As of February 28th, there was short interest totaling 5,150,000 shares, an increase of 10.8% from the February 13th total of 4,650,000 shares. Based on an average daily volume of 1,080,000 shares, the short-interest ratio is presently 4.8 days.
View 89bio's Short Interest
.

When is 89bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our ETNB earnings forecast
.

How were 89bio's earnings last quarter?

89bio, Inc. (NASDAQ:ETNB) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by $0.35.

What other stocks do shareholders of 89bio own?
When did 89bio IPO?

(ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is 89bio's stock symbol?

89bio trades on the NASDAQ under the ticker symbol "ETNB."

Who are 89bio's major shareholders?

89bio's stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (17.71%), Millennium Management LLC (3.08%), Marshall Wace LLP (2.94%), Point72 Asset Management L.P. (2.03%), Two Sigma Investments LP (1.41%) and Citigroup Inc. (1.07%). Insiders that own company stock include Gregory Grunberg, Longitude Capital Partners Iii, Ollin B Sykes, Orbimed Advisors Llc, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends
.

How do I buy shares of 89bio?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 89bio's stock price today?

One share of ETNB stock can currently be purchased for approximately $16.94.

How much money does 89bio make?

89bio (NASDAQ:ETNB) has a market capitalization of $884.78 million. The company earns $-102,030,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis.

How can I contact 89bio?

89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The official website for the company is www.89bio.com. The company can be reached via phone at 415-432-9270 or via email at investors@89bio.com.

This page (NASDAQ:ETNB) was last updated on 3/24/2023 by MarketBeat.com Staff